Omada Health vs GeneDx
OMDA and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OMDA and WGS compare
GeneDx is the larger company, worth 1.8 times as much as Omada Health ($1.5B against $877M).
Omada Health grew revenue faster over the last twelve months (43.3% versus 14.6% for GeneDx).
Omada Health keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with −24.1% at GeneDx.
Omada Health scores higher on the StockData Score (13 against 3 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OMDA | WGS |
|---|---|---|
| Size and price | ||
| Market cap | $877M | $1.5B |
| Share price | $14.33 | $51.87 |
| Change, 1 year | −33.2% | −62.9% |
| Change, 5 years | – | −78.4% |
| Beta (5Y) | 2.29 | 1.99 |
| Employees | 916 | 1,300 |
| StockData Score | ||
| Total score | 13 (better) | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.6× (better) | 3.4× |
| P/B | 3.2× (better) | 6.3× |
| EV/EBITDA | 48.5× | – |
| P/FCF | 31.2× | – |
| FCF yield | 3.2% (better) | −6.5% |
| Fair value | $9.16 | $32.27 |
| Margin of safety | −56.4% (better) | −60.7% |
| Growth | ||
| Revenue growth (TTM) | 43.3% (better) | 14.6% |
| Revenue growth, 5Y average | – | 19.0% |
| Net income growth (TTM) | – | −5431% |
| EPS growth (TTM) | – | −6400% |
| Profitability | ||
| Gross margin | 70.7% (better) | 68.7% |
| Operating margin | 2.1% (better) | −21.6% |
| Net margin | 4.2% (better) | −24.1% |
| FCF margin | 8.5% (better) | −22.0% |
| Return on equity | 5.7% (better) | −41.4% |
| Return on invested capital | 28.2% (better) | −38.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.60 (better) |
| Interest coverage | 22.4× | – |
| Current ratio | 4.18 (better) | 4.16 |
| Altman Z-score | 7.03 (better) | 0.16 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 85.9% | 107% |
| Held by insiders | 5.4% | – |
| Insider net buying, 12 months | −$14.6M | $91.2M (better) |
| Short interest, % of float | 15.8% | – |
Go deeper
- OMDA stock overview
- OMDA income statement
- OMDA valuation and score
- WGS stock overview
- WGS income statement
- WGS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.